###### Key messages

-   Vitamin D deficiency is common in paediatric lupus.

-   In this population, vitamin D deficiency is associated with not only traditional risk factors, but also chronic inflammation markers such as hsCRP.

Introduction {#s1}
============

Over the last three decades, systemic lupus erythematosus (SLE)-related mortality has decreased in all areas except for cardiovascular disease (CVD).[@R1] Women with SLE less than 40 years of age are at a 50-fold increased risk of myocardial infarction compared with control populations.[@R2] This increase in risk cannot be attributed solely to traditional cardiovascular risk factors; both immune and vascular pathology in SLE are postulated to contribute.[@R3] [@R4]

Vitamin D deficiency has emerged as a potential risk factor for CVD.[@R5] Vitamin D status is mainly determined by the level of circulating 25-hydroxyvitamin D \[25(OH)D\], which is converted into an active secosteroid hormone, 1,25-dihydroxyvitamin D \[1,25(OH)~2~D\], by the kidney and cells of the immune system such as B cells, T cells and dendritic cells. The activated hormone then regulates transcription of several inflammatory cytokines.[@R6] Studies have shown that vitamin D deficiency (widely defined as a serum 25(OH)D concentration less than 20 ng/mL) is common in SLE and has been associated with photosensitivity, fatigue, renal disease, disease activity and proteinuria.[@R7] In vitro, 1,25(OH)~2~D blocks dendritic cell differentiation, lowers interleukin-12 secretion and modulates B- and T-lymphocyte proliferation and function.[@R12] Differentiation of dendritic cells and release of type I interferon are important in the pathogenesis of SLE.[@R16]

In epidemiological studies of the general population, low vitamin D levels have been associated with CVD, hypertension, diabetes, HDL and LDL-cholesterol, and surrogate measurements of cardiovascular risk such as coronary artery calcification and carotid intima media thickness (CIMT).[@R5] One prospective study found that serum 25(OH)D \<15 ng/mL had a multivariable-adjusted HR of 1.62 (95% CI 1.11 to 2.36, p=0.01) for incident CVD events.[@R17] Another study of subjects with dyslipidemia found that the addition of vitamin D to atorvastatin synergistically lowered total and LDL-cholesterol levels.[@R18] There are no studies that have evaluated the relationship between vitamin D status, inflammation and subclinical vascular disease in paediatric subjects with lupus.

The Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) trial was originally designed to prospectively assess the effect of atorvastatin on progression rate of CIMT in 221 children and young adults (aged 10--21 years) with SLE.[@R19] Subjects were randomised to 36 months of atorvastatin (10--20 mg/day based on weight) versus placebo treatment in addition to their ongoing treatment of SLE. Primary results showed no significant difference in mean--mean CIMT progression between treatment and placebo groups; however, the primary results confirmed that children and adolescents with SLE have subclinical atherosclerosis with CIMT progression rates greater than reported in healthy children and children with familial hyperlipidaemia.[@R19] The objective of this subanalysis was to use samples prospectively obtained during participation in the APPLE study to evaluate the relationship between vitamin D status and baseline measures of inflammation and CVD risk in children with SLE.

Materials and methods {#s2}
=====================

Subjects {#s2a}
--------

Participants in the 3-year APPLE trial were randomised to placebo or atorvastatin, and CIMT progression was measured. The design and methods of the APPLE trial have been reported previously.[@R19] SLE was classified by American College of Rheumatology criteria, and participants were enrolled from 21 North American centres. Patients were excluded from the study if they had baseline fasting total cholesterol \>350 mg/dL, familial hypercholesterolaemia, nephrotic syndrome, renal insufficiency, liver disease or were pregnant or nursing. Participants were randomised to daily atorvastatin (\>50 kg: 10 mg/day, increasing to 20 mg/day at day 30; ≤50 kg: 10 mg/day). Hydroxychloroquine, low-dose aspirin, multivitamins containing folate and American Heart Association Therapeutic Lifestyle Changes diet were recommended. Treatment for SLE was determined by the treating paediatric rheumatologist.

CIMT measurements {#s2b}
-----------------

Two baseline CIMT examinations were performed using an ultrasound protocol described previously.[@R20] All ultrasound scans were centrally read (Ward A. Riley Ultrasound Center, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA) by a single experienced reader using Image Pro software (Media Cybernetics, Bethesda, Maryland, USA). Standardised longitudinal B-mode images were collected for three arterial segments defined as the common carotid artery, the carotid bifurcation and the proximal 10 mm of the internal carotid artery. For a set of 68 studies reread to evaluate intrareader reliability, the intraclass correlation coefficient was 0.74 (95% CI 0.61 to 0.83) for mean--mean common and 0.71 (95% CI 0.56 to 0.81) for mean--max CIMT measurements. The combination of three arterial segments, two walls and two sides of the neck provided a set of 12 CIMT measurement sites, each imaged from four angles. The 12 maximum CIMT values were then averaged to determine the mean--max CIMT over near and far walls of the right and left common carotid artery, carotid bifurcation and internal carotid artery. For each of the four measurement sites in the common carotid artery, a mean CIMT value defined as the average of the four angle-specific mean CIMTs was also calculated. The four mean CIMT values were then averaged to determine the mean--mean common CIMT.

Markers of atherosclerosis and SLE disease severity {#s2c}
---------------------------------------------------

Other assessments including fasting lipid levels and disease activity scores (SELENA-SLEDAI, SLICC, PedsQL 4.0) were obtained as previously described.[@R20] IRB approval was obtained for the original APPLE trial and additionally for this secondary analysis.

Serum 25(OH)D determinations {#s2d}
----------------------------

Frozen serum collected from the APPLE trial at baseline stored in −80° freezers were shipped in one batch to the laboratory of Dr Vin Tangpricha at Emory University. Serum 25(OH)D was measured by chemiluminescent assay using the IDS iSYS automated system (Fountain Hills, Arizona, USA). Intraassay and interassay coefficients of variation for serum 25(OH)D were 1.8--4.0% and 10.1--13.0%, respectively. The laboratory participates in a vitamin D external quality control assessment schema (<http://www.deqas.org>) and the National Institute of Arthritis (NIH) standard quality control programme for vitamin D and tested proficient in the measurement of 25(OH)D during the study period.

Statistical analysis {#s2e}
--------------------

All statistical analyses were performed using SAS V.9.2 statistical software (SAS Inc, Cary, North Carolina, USA). All statistical tests were two-sided with p values less than 0.05 considered significant for this analysis. This study was an analysis of baseline characteristics only and did not evaluate subjects over time after randomisation. Baseline characteristics were summarised using descriptive statistics, with continuous data presented as means and SDs and dichotomous or ordinal data presented as percentages. Differences between groups were assessed with either the χ^2^ test or the non-parametric Wilcoxon\'s test. For baseline serum 25(OH)D level and vitamin D deficiency \[25(OH)D levels \<20 ng/mL\] respectively, models were constructed to examine each relationship with a select group of baseline variables or predictors. These predictors include variables collected as part of the APPLE trial including (1) known risk factors for vitamin D deficiency, including race, season, latitude, multivitamin use, body mass index and socioeconomic status; (2) SLE-specific factors including duration of illness, disease activity, high sensitivity C-reactive protein (hsCRP) and proteinuria; and (3) traditional cardiovascular risk factors including fasting lipids and baseline CIMT. To examining the relationship between each predictor and the continuous outcome of serum 25(OH)D level, separate linear regression models were estimated for each predictor. For continuous predictors, scatter plots with an overlay of locally weighted scatterplot smoothing (LOESS) were constructed to examine the relationships between continuous variables and the outcome of serum 25(OH)D. Transformations were considered for gross departures from linearity. A multivariable linear regression model was constructed with the outcome serum 25(OH)D level at baseline and the list of selected predictors. A backwards elimination variable selection procedure was implemented to reduce the variables in the model to be the most impactful and parsimonious. Finally, a multivariable logistic regression model was constructed with the outcome vitamin D deficiency at baseline and the list of selected predictors. To examine the relationship between each predictor and the binary outcome of vitamin D deficiency at baseline, separate logistic regression models were estimated for each predictor. For continuous predictors, plots of restricted cubic splines were constructed to examine the relationships between continuous variables and the outcome of vitamin D deficiency. Transformations were considered for gross departures from linearity. A backwards elimination variable selection procedure was implemented to reduce the numbers of variables in the model to be the most impactful and parsimonious.

Results {#s3}
=======

Baseline characteristics {#s3a}
------------------------

A total of 201/221 (91%) of APPLE subjects had available baseline samples and were included in the analysis. Participants were recruited from 21 North American sites. Participants were 83% female, 51% Caucasian, 27% African-American, 23% Hispanic and had a median age of 16 (IQR 14 to 19) years at entry into the study. Median duration of SLE was 24 (IQR 7 to 45) months. Mean SLEDAI score at time of entry was 4 (IQR 2 to 6) points; 75% had had a SLICC score of 0. Children with active nephrotic syndrome, hypercholesterolaemia and renal insufficiency were excluded, but 41% had a history of glomerulonephritis, 33% had a history of hypertension and median creatinine clearance was 134 (IQR 119 to 155) mL/min. Median fasting total cholesterol levels were 148 mg/dL. Overall, 73% of subjects reported taking multivitamins and 67% reported taking vitamin D supplementation at baseline. [Table 1](#LUPUS2014000011TB1){ref-type="table"} shows the baseline demographics.

###### 

Baseline characteristics of APPLE cohort by vitamin D status

  -------------------------------------------------------------------------------------------------------
  Variable                            25(OH)D ≥20 ng/mL\   25(OH)D\        All patients\     p Value
                                      n=140                \<20 ng/mL\     n=201             
                                                           n=61                              
  ----------------------------------- -------------------- --------------- ----------------- ------------
  Female                              114 (81.4%)          53 (86.9%)      167 (83.1%)       0.34

  Age, years (SD)                     15.4 (2.6)           16.3 (2.8)      15.7 (2.7)        0.05

  Latitude (SD)\*                     39.5 (3.4)           38.9 (3.0)      39.3 (3.3)        0.09

  Season†                                                                                    

   1st quarter                        18 (12.9%)           18 (29.5%)      36 (17.9%)        **\<0.01**

   2nd quarter                        36 (25.7%)           18 (29.5%)      54 (26.9%)        

   3rd quarter                        43 (30.7%)           9 (14.8%)       52 (25.9%)        

   4th quarter                        43 (30.7%)           16 (26.2%)      59 (29.4%)        

  Race                                                                                       

   White                              84 (60.0%)           18 (29.5%)      102 (50.7%)       **\<0.01**

   Black                              27 (19.3%)           27 (44.3%)      54 (26.9%)        

   Asian                              15 (10.7%)           4 (6.6%)        19 (9.5%)         

   Native American                    3 (2.1%)             0 (0.0%)        3 (1.5%)          

   Native Hawaiian                    4 (2.9%)             1 (1.6%)        5 (2.5%)          

  Hispanic or Latino                  29 (20.7%)           18 (29.5%)      47 (23.4%)        0.18

  History of smoking                  3 (2.1%)             3 (4.9%)        6 (3.0%)          0.37

  Postpubertal                        91/114 (79.8%)       46/53 (86.8%)   137/167 (82.0%)   0.28

  Household income                                                                           

   \<25 000                           32/131 (24.4%)       25/56 (44.6%)   57/187 (30.5%)    0.13

   25--49 999                         36/131 (27.5%)       15/56 (26.8%)   51/187 (27.3%)    

   50--74 999                         25/131 (19.1%)       6/56 (10.7%)    31/187 (16.6%)    

   75--99 999                         19/131 (14.5%)       5/56 (8.9%)     24/187 (12.8%)    

   100--149 999                       12/131 (9.2%)        4/56 (7.1%)     16/187 (8.6%)     

   \>150 000                          7/131 (5.3%)         1/56 (1.8%)     8/187 (4.3%)      

  BMI percentile (SD)                 72.3 (24.0)          71.5 (28.0)     72.1 (25.2)       0.77

  Duration of lupus, months (SD)      26.7 (26.1)          38.8 (33.2)     30.4 (28.9)       **0.01**

  SLEDAI (SD)                         4.2 (3.9)            5.3 (4.4)       4.5 (4.0)         0.10

  SLICC=0                             111 (79.3%)          40 (65.6%)      151 (75.1%)       **0.04**

  Hypertension                        42/135 (31.1%)       23/60 (38.3%)   65/195 (33.3%)    0.32

  Glomerulonephritis                  52/139 (37.4%)       29/61 (47.5%)   81/200 (40.5%)    0.18

  Creatinine clearance (SD)           136.5 (27.0)         143.8 (40.6)    138.7 (31.8)      0.31

  Timed urine protein, mg/24 h (SD)   142.0 (212.2)        365.5 (790.8)   214.6 (491.5)     0.07

  Serologies                                                                                 

   Lupus anticoagulant                50/135 (37.0%)       18/55 (29.5%)   68/190 (35.8%)    0.23

   Anticardiolipin ab                 59/137 (43.1%)       27/59 (45.8%)   86/196 (43.9%)    0.57

   dsDNA                              113/140 (80.7%)      50/61 (82.0%)   163/201 (81.1%)   0.73

  Corticosteroid usage                116 (82.9%)          47/60 (78.3%)   163/200 (81.5%)   0.45

  ACE inhibitor usage                 32/140 (22.9%)       17/60 (28.3%)   49/200 (24.5%)    0.41

  Vitamin D                           94/140 (67.1%)       39/60 (65.0%)   133/200 (66.5%)   0.77

  Calcium                             87/140 (62.1%)       33/60 (55.0%)   120/200 (60.0%)   0.35

  Baseline hsCRP (SD)                 2.2 (7.5)            4.6 (10.4)      2.9 (8.4)         **\<0.01**

  Homocysteine (SD)                   7.3 (2.6)            7.7 (3.8)       7.4 (3.0)         0.93

  Lipids (SD)                                                                                

   Total cholesterol                  152.9 (39.3)         158.6 (36.5)    154.7 (38.5)      0.16

   HDL cholesterol                    47.1 (13.8)          43.5 (10.8)     46.0 (13.0)       0.24

   LDL cholesterol                    83.6 (31.8)          91.6 (30.0)     86.0 (31.4)       **0.03**

   Triglycerides                      111.4 (54.4)         123.5 (92.9)    115.2 (68.6)      0.93

  Lipoprotein A (SD)                  21.8 (26.5)          24.3 (22.4)     22.6 (25.3)       0.22

  Baseline mean--mean common CIMT     0.467 (0.042)        0.471 (0.044)   0.468 (0.042)     0.57

  Baseline mean--max CIMT             0.580 (0.055)        0.590 (0.056)   0.583 (0.055)     0.23
  -------------------------------------------------------------------------------------------------------

Bold denotes p values less than 0.05 to indicate statistical significance.

\*Latitude is defined as the degree of latitude of the subject study centre. Latitude ranged from 32 to 48°.

†Season is defined as follows: 1st 1/1--3/31, 2nd 4/1--6/30, 3rd 7/1--9/31, 4th 10/1--12/31.

APPLE, Atherosclerosis Prevention in Pediatric Lupus Erythematosus; CIMT, carotid intima medial thickness; hsCRP, high-sensitivity C-reactive protein.

Vitamin D status {#s3b}
----------------

Overall, 61/201 (30%) had vitamin D deficiency at baseline and 139 (69%) had levels \<30 ng/mL, indicating vitamin D insufficiency; 12 subjects (6%) had levels less than 10 ng/mL indicating severe vitamin D deficiency. Median serum 25(OH)D levels were 25.8 ng/mL (IQR 18.2 to 31.7).

Associations with vitamin D status {#s3c}
----------------------------------

### Univariable analysis {#s3c1}

Vitamin D deficiency as a dichotomous outcome was associated with first quarter season, African-American race, longer SLE disease duration, increased proportions of participants with SLICC damage index scores greater than 0, increased baseline hsCRP and increased LDL-cholesterol (see [table 1](#LUPUS2014000011TB1){ref-type="table"}). Evaluation of vitamin D status as a continuous outcome did not change associations with season, race, disease duration, SLICC damage index and baseline hsCRP. The association with LDL-cholesterol trended towards significance (p=0.06). Log transformation of hsCRP improved model fit but did not change the underlying association (p\<0.01). Using vitamin D status as a continuous outcome, log transformation of timed urine protein improved model fit with a significant association between vitamin D deficiency and increasing proteinuria (p=0.03). With linear regression, lower vitamin D status was associated with increased mean--max CIMT (p=0.01) and body mass index percentile (p=0.04).

### Multivariable analysis {#s3c2}

Using the same variables, a multivariable logistic model was constructed using backward, forward and stepwise variable selection procedures and compared with backward and forward results. In all three selection procedures, vitamin D deficiency was associated with age, latitude, season, minority status and hsCRP. Duration of SLE was included in initial variable selection along with age, but was not selected for the final model. Timed urine proteinuria trended towards significance (p=0.06) and was included in all models (see [table 2](#LUPUS2014000011TB2){ref-type="table"}).

###### 

Multivariable logistic modelling of vitamin D deficiency \[serum 25(OH)D \<20 ng/mL\]

                                Odds ratio   95% CI          p Value
  ----------------------------- ------------ --------------- -----------------
  Age                           1.28         1.09 to 1.50    **0**.**002**
  Latitude\*                    0.87         0.76 to 0.99    **0**.**034**
  Season†                                                    **\<0**.**050**
   1st quarter                  2.83         0.87 to 9.23    0.084
   2nd quarter                  1.23         0.45 to 3.36    0.685
   3rd quarter                  0.57         0.19 to 1.75    0.327
  Minority status‡              17.47        5.22 to 58.48   **\<0**.**001**
  Log timed urine proteinuria   2.47         0.96 to 6.34    0.060
  Log hsCRP                     1.40         1.07 to 1.83    **0**.**015**

Bold denotes p values less than 0.05 to indicate statistical significance.

\*Latitude is defined as the degree of latitude of the subject study centre. Latitude ranged from 32 to 48°.

†Season is defined as follows: 1st 1/1--3/31, 2nd 4/1--6/30, 3rd 7/1--9/31, 4th 10/1--12/31, with 4th quarter as the referent season.

‡Minority status is all races/ethnicities compared with the referent of white, non-Hispanic.

hsCRP, high-sensitivity C-reactive protein.

Discussion {#s4}
==========

In this secondary analysis of the baseline evaluation of paediatric subjects with SLE enrolled into a large randomised trial, we showed significant independent associations between vitamin D deficiency and age, body mass index, season, minority status and latitude, which are consistent with larger epidemiological studies of the general population. Clearly, increased age, increased body mass index, late season, decreased UV exposure and darker skin pigmentation are well-established independent risk factors for vitamin D deficiency, and many of these risk factors were present in the APPLE cohort. At entry into APPLE, most study participants had established SLE disease with a mean duration of 30 months. Almost 75% of participants reported taking regular multivitamins, and 67% reported taking vitamin D supplementation. Despite this, our results indicate that vitamin D deficiency continues to be relatively common in paediatric SLE with 30% of participants having deficient levels of vitamin D (25(OH)D less than 20 ng/mL) and 69% having insufficient levels of vitamin D (25(OH)D less than 30 ng/mL), consistent with findings from Kamen *et al* and others.[@R7]^--^[@R10]

In addition to the traditional risk factors of race, season and body mass index, this study highlights associations between vitamin D deficiency and SLE-specific factors such as disease duration, SLICC damage index, hsCRP and proteinuria. Usage of corticosteroids and ACE inhibitors were not associated with vitamin D deficiency in this study. In our analysis, we found no association between corticosteroid usage or dosage by weight and vitamin D levels in this cohort; however, we did not have enough data to look at history of corticosteroid usage in this population. In the original analysis of the APPLE baseline data, there was an association between corticosteroid usage and baseline CIMT, but the relationship was non-monotonic and nonlinear with different steroid dosages by weight.[@R20] In previous cross-sectional studies of SLE, serum 25(OH)D levels less than 20 ng/mL were associated with photosensitivity, fatigue, renal disease, increased body mass index and elevated SLEDAI scores.[@R7]^--^[@R10] In a recent prospective SLE cohort, treatment with vitamin D2 over 128 weeks to an increase of 20 ng/mL in 25(OH)D level was associated with a 21% decrease in the odds of having a high SELENA-SLEDAI score and a 15% decrease in the odds of having significant proteinuria, although the clinical improvement was relatively modest.[@R21] We have previously reported that children with SLE and proteinuria have increased vitamin D binding protein in their urine, which correlates with decreased serum albumin and serum 25(OH)D.[@R11] Decreased serum vitamin D binding protein may diminish the half-life of serum 25(OH)D since 25(OH)D is protein-bound and crosses the cell membrane complexed with vitamin D binding protein. The association between vitamin D deficiency and timed urine protein in this cohort is also consistent with this relationship.

The relationship between vitamin D status and the inflammatory marker CRP has been previously described in adults with SLE, specifically in the LAPS study, a randomised study of atorvastatin in adults with lupus.[@R22] In LAPS, a 25(OH)D level of greater than 21 ng/mL was associated with lower cross-sectional baseline CRP levels. CRP is associated with higher SLE disease activity measured by physician\'s global assessment or SLEDAI and has been associated with increased serositis and arthritis.[@R23] In newly diagnosed patients with SLE, hsCRP levels correlate with disease activity.[@R26] For the first time in paediatric lupus, we show an independent association between vitamin D deficiency and elevated hsCRP, which persisted despite adjusting for traditional vitamin D deficiency risk factors. Although the cross-sectional design of this study precludes causal inferences, the association between vitamin D and hsCRP suggests that vitamin D may play a role in the chronic inflammation seen in SLE.

Although univariate modelling showed a relationship between increased mean--max CIMT and vitamin D deficiency, this association disappeared in the multivariate model. It is possible that adjusting for hsCRP, other confounders, or a loss of power due to limited sample size diminished the ability to see a difference in the multivariate model. In further analysis of the 3-year progression of CIMT seen during the study, we found evidence of interaction between vitamin D status and the effect of atorvastatin on mean--max CIMT progression over 3 years.[@R27] The sample size in this analysis is relatively small for multivariate analysis of CIMT; however, the APPLE study is the largest North American trial cohort of paediatric SLE to date and larger numbers of participants with detailed clinical characterisation linked to available serum samples are not available for analysis. The associations seen between vitamin D, hsCRP and CIMT suggest that vitamin D, through a role in the inflammatory pathway, may be associated with CIMT. Given that this is an exploratory analysis, these results should be interpreted cautiously as hypothesis generating rather than hypothesis testing. This scenario mirrors recent data from another chronic inflammatory condition, treated HIV infection, where vitamin D deficiency was also associated with inflammatory markers and CIMT.[@R28]

In summary, vitamin D deficiency is common in paediatric lupus and is independently associated with elevated hsCRP, a marker of inflammation, which predicts CVD risk. In this population, vitamin D deficiency was associated with traditional risk factors such as season, race, latitude, and age, but also with SLE-specific factors including hsCRP and proteinuria. Observed association differences between univariable and multivariable modelling may be related to confounding or loss of power and requires further study. The association between vitamin D deficiency and hsCRP is novel in paediatric lupus and suggests that vitamin D deficiency may independently contribute to heightened inflammation and cardiovascular risk in this high-risk population. Further analyses of the APPLE cohort are ongoing to examine possible interactions between vitamin D deficiency and atorvastatin in the 3-year CIMT progression rates and hsCRP.
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